Últimas noticias sobre Lakeside Holding (NASDAQ:LSH) Bolsa

Lakeside Holding

Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.

Lakeside Holding Ltd

<p>Barclays  analyst Jared Shaw   maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Overweight and raises the price target from $23 to $25.</p>


News

Price Target

Analyst Ratings

Barclays Maintains Overweight on First Horizon, Raises Price Target to $25

<p>Barclays  analyst Marc Solecitto   maintains Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) with a Overweight and raises the price target from $18 to $22.</p>


Barclays Maintains Overweight on Energy Transfer, Raises Price Target to $22

<p>Barclays  analyst Jeffrey Bernstein   maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Overweight and raises the price target from $192 to $206.</p>


Barclays Maintains Overweight on Darden Restaurants, Raises Price Target to $206

<p>Barclays  analyst Jared Shaw   maintains BankUnited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) with a Equal-Weight and lowers the price target from $45 to $44.</p>


Barclays Maintains Equal-Weight on BankUnited, Lowers Price Target to $44

Offerings

MNPR

Monopar Therapeutics Prices $40M Public Offering Of Common Stock Of 798,655 Shares At $23.79/Share; Concurrent Private Placement Of Pre-Funded Warrants To Purchase 882,761 Shares At $23.789/Pre-Funded Warrant

<p>Keybanc  analyst Eric Gonzalez   maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Overweight and raises the price target from $194 to $200.</p>


Keybanc Maintains Overweight on Darden Restaurants, Raises Price Target to $200

BATL

Battalion Oil Terminates Merger Agreement With Fury Resources Due To Financing Issues, Cancels Stockholder Meeting, And Reports Strong Operations With Above-Plan Monument Draw Drilling And Vermejo Wells Exceeding Production Expectations At Reduced Costs

Cyngn Prices $20M Follow On Offering

Biotech

General

RENB

Renovaro Enters Collaboration With Nebul For Early Disease Detection

<p>Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) in the last three months.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Moodys, revealing an average target of $509.36, a high estimate of $565.00, and a low estimate of $459.00. This upward trend is apparent, with the current average reflecting a 5.51% increase from the previous average price target of $482.78.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734703276_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Moodys among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Christiansen</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$565.00</td>
<td>-</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$481.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$459.00</td>
<td>$454.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$510.00</td>
<td>$495.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$543.00</td>
<td>$536.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$512.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$464.00</td>
<td>$455.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$462.00</td>
<td>$451.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$536.00</td>
<td>$492.00</td>
</tr>
<tr>
<td>David Motemeden</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$521.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Moodys. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moodys compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Moodys's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Moodys's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MCO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Moodys analyst ratings.</strong></a></p>
<h2>Discovering Moodys: A Closer Look</h2>
<p>Moody's, along with S&amp;P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and about half the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.</p>
<h3>Moodys: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Moodys's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>23.17%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Moodys's net margin excels beyond industry benchmarks, reaching <strong>29.45%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Moodys's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>13.9%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Moodys's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.47%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.03</strong>, caution is advised due to increased financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Moodys Through The Eyes Of 11 Analysts

<p>6 analysts have expressed a variety of opinions on Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $65.67, a high estimate of $77.00, and a low estimate of $60.00. A decline of 3.18% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734703266_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Ionis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Allison Bratzel</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$77.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ionis Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Ionis Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ionis Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IONS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ionis Pharmaceuticals analyst ratings.</strong></a></p>
<h2>All You Need to Know About Ionis Pharmaceuticals</h2>
<p>Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.</p>
<h3>Ionis Pharmaceuticals's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> Ionis Pharmaceuticals's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-7.21%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Ionis Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-104.98%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Ionis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-30.34%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-4.87%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Ionis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.18</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IONS

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts

BCAB

BioAtla Announces $9.2M Registered Direct Offering Of 9,679,158 Shares At $1.19/Share

<p>8 analysts have shared their evaluations of FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $331.5, with a high estimate of $366.00 and a low estimate of $288.00. This current average has increased by 3.23% from the previous average price target of $321.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734703252_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of FedEx by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$320.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Rick Paterson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$365.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$366.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>David Vernon</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$316.00</td>
<td>$337.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$365.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$331.00</td>
<td>$301.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$301.00</td>
<td>-</td>
</tr>
<tr>
<td>Rick Paterson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$288.00</td>
<td>$317.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to FedEx. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of FedEx compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of FedEx's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into FedEx's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FDX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on FedEx analyst ratings.</strong></a></p>
<h2>Delving into FedEx's Background</h2>
<p>FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2024, which ended in May, FedEx derived 47% of revenue from its express division, 37% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.</p>
<h3>Key Indicators: FedEx's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Challenges:</strong> FedEx's revenue growth over 3 months faced difficulties. As of 31 August, 2024, the company experienced a decline of approximately <strong>-0.47%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> FedEx's net margin excels beyond industry benchmarks, reaching <strong>3.67%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> FedEx's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.9%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> FedEx's ROA excels beyond industry benchmarks, reaching <strong>0.91%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.39</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing FedEx: Insights From 8 Financial Analysts

<p>Wells Fargo  analyst Christian Wetherbee   maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Equal-Weight and raises the price target from $305 to $320.</p>


Wells Fargo Maintains Equal-Weight on FedEx, Raises Price Target to $320

<p>During the last three months, 4 analysts shared their evaluations of Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.36, a high estimate of $10.50, and a low estimate of $8.20. This upward trend is evident, with the current average reflecting a 4.0% increase from the previous average price target of $9.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734703241_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Legacy Education is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$10.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$8.75</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.75</td>
<td>$8.25</td>
</tr>
<tr>
<td>Jeff Cohen</td>
<td>Ladenburg Thalmann</td>
<td>Announces</td>
<td>Buy</td>
<td>$8.20</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Legacy Education. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Legacy Education compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Legacy Education's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Legacy Education's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LGCY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Legacy Education analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Legacy Education: A Closer Look</h2>
<p>Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.</p>
<h3>Breaking Down Legacy Education's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Legacy Education's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>35.09%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Legacy Education's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>14.93%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Legacy Education's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.61%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Legacy Education's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.88%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Legacy Education's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.29</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LGCY

4 Analysts Have This To Say About Legacy Education

NFLX

Netflix Secures Exclusive U.S. Rights To FIFA Women's World Cup For 2027 And 2031, Covering All Languages With English And Spanish Telecasts

<p><strong>Centene's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has risen 7.58% since its last report. The company recently reported that it has <strong>16.31 million shares sold short</strong>, which is 3.69% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.19 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Centene Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734703224_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Centene has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 5.40%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

(CNC) - Analyzing Centene's Short Interest

<p>During the last three months, 11 analysts shared their evaluations of Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $209.73, along with a high estimate of $245.00 and a low estimate of $184.00. This current average represents a 14.08% decrease from the previous average price target of $244.09. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734703219_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Cintas's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$184.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$202.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Stephanie Moore</td>
<td>Jefferies</td>
<td>Adjusts</td>
<td>Hold</td>
<td>$200.00</td>
<td>$730.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$236.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$191.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$215.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$209.00</td>
<td>$194.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cintas. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cintas compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Cintas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Cintas's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CTAS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Cintas analyst ratings.</strong></a></p>
<h2>Get to Know Cintas Better</h2>
<p>Cintas has roots tracing back to 1929, during which the Farmer family cleaned and re-sold dirty rags to manufacturing plants in Ohio. The firm has grown its business organically and through acquisitions, and today Cintas acts as a one-stop outsourcing partner for businesses. Cintas will design, manufacture, collect, and clean every employee uniform for a small weekly sum, taking on the upfront capital expense itself. In the same stop, Cintas can also replace soiled or depleted mats, mops, trash liners, towels, first aid, fire, and cleaning products. Businesses value an outsourcing partner like Cintas as it simplifies operations and leaves noncore tasks with high regulatory standards in the hands of professionals.</p>
<h3>Cintas: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Cintas showcased positive performance, achieving a revenue growth rate of <strong>6.8%</strong> as of 31 August, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>18.0%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Cintas's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>10.8%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Cintas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.94%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Cintas's debt-to-equity ratio is below the industry average. With a ratio of <b>0.71</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CTAS

Cintas Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

<p><strong>Applied Optoelectronics's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NYSE">AAOI</a>) short percent of float has fallen 5.67% since its last report. The company recently reported that it has <strong>9.27 million shares sold short</strong>, which is 21.48% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.3 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Applied Optoelectronics Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734703218_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Applied Optoelectronics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Applied Optoelectronics's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Applied Optoelectronics's peer group average for short interest as a percentage of float is 6.06%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


AAOI

Peering Into Applied Optoelectronics's Recent Short Interest

<p>Keefe, Bruyette &amp; Woods  analyst Kyle Voigt   maintains Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) with a Market Perform and lowers the price target from $215 to $167.</p>


HLNE

Keefe, Bruyette & Woods Maintains Market Perform on Hamilton Lane, Lowers Price Target to $167

IPO roundup: WEBTOON Entertainment, LandBridge, and more

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>We have the biggest pre-market stock movers that traders are going to want to start the week with on Monday morning!</p>



<p>Moving stocks this morning are Roaring Kitty news, a company filing for bankruptcy and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Loop Media </strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/lptv-stock-quote/"><strong>LPTV</strong></a>) stock is rocketing 88% alongside heavy pre-market trading.</li>



<li><strong>Golden Heaven</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/"><strong>GDHG</strong></a>) shares are soaring close to 43% with strong early morning trading.</li>



<li><strong>Chewy </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/chwy-stock-quote/"><strong>CHWY</strong></a>) stock is surging almost 19% as Roaring Kitty <a href="https://www.cnbc.com/2024/07/01/chewy-shares-rally-20percent-after-sec-filing-reveals-roaring-kitty-keith-gill-has-6point6percent-stake.html">takes a stake in the company</a>.</li>



<li><strong>Mesoblast</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/meso-stock-quote/"><strong>MESO</strong></a>) shares are increasing more than 16% on a <a href="https://www.nasdaq.com/press-release/mesoblast-file-biologics-license-application-ryoncilr-fda-approval-next-week-2024-07">new biologics license application</a>.</li>



<li><strong>Barfresh Food</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/brfh-stock-quote/"><strong>BRFH</strong></a>) stock is rising over 16% despite a lack of news this morning.</li>



<li><strong>Nukkleus </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/"><strong>NUKK</strong></a>) shares are gaining nearly 15% with strong pre-market trading.</li>



<li><strong>Incannex Healthcare</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ixhl-stock-quote/"><strong>IXHL</strong></a>) stock is climbing more than 12% without any clear news today.</li>



<li><strong>Tempus AI</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tem-stock-quote/"><strong>TEM</strong></a>) shares are getting an over 13% boost <a href="https://www.tradingview.com/news/reuters.com,2024:newsml_L1N3IQ0UH:0-tempus-ai-rallies-in-three-day-recovery-still-below-ipo-price/">with a recent rally</a> after its initial public offering (<a href="https://investorplace.com/stock-quotes/ipo-stock-quote/"><strong>IPO</strong></a>) last month.</li>



<li><strong>Lion Group</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/lghl-stock-quote/"><strong>LGHL</strong></a>) stock is jumping more than 13% with heavy early morning trading today.</li>



<li><strong>Hollysys Automation Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/holi-stock-quote/"><strong>HOLI</strong></a>) shares are up over 13% without any obvious news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Delta Apparel</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/dla-stock-quote/"><strong>DLA</strong></a>) stock is plummeting more than 34% despite no clear news this morning.</li>



<li><strong>Chicken Soup for the Soul Entertainment</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/csse-stock-quote/"><strong>CSSE</strong></a>) shares are diving over 20% after <a href="https://fortune.com/2024/06/29/redbox-dvd-kiosks-chicken-soup-for-the-soul-chapter-11-bankruptcy-filing/">filing for Chapter 11 bankruptcy</a>.</li>



<li><strong>African Agriculture</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aagr-stock-quote/"><strong>AAGR</strong></a>) stock is tumbling more than 14% alongside recent volatility.</li>



<li><strong>Chicken Soup for the Soul Entertainment</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cssep-stock-quote/"><strong>CSSEP</strong></a>) shares are taking an over 14% beating with the bankruptcy filing.</li>



<li><strong>Chicken Soup for the Soul Entertainment, Inc. &ndash; 9.50% Notes due 2025</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cssen-stock-quote/"><strong>CSSEN</strong></a>) are sliding more than 12% alongside the bankruptcy news.</li>



<li><strong>Wang &amp; Lee</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/wlgs-stock-quote/"><strong>WLGS</strong></a>) stock is falling 12% after a Friday rally.</li>



<li><strong>Lakeside </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) shares are dropping over 10% this morning.</li>



<li><strong>Li-Cycle</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/licy-stock-quote/"><strong>LICY</strong></a>) stock is decreasing more than 10% on an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318425152&amp;type=PDF&amp;symbol=LICY&amp;cdn=adb9d0bf10804596acf67ff3f07cb9bd&amp;companyName=Li-Cycle+Holdings+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-28">at-market sales agreement</a>.</li>



<li><strong>AgriForce Growing Systems</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/agri-stock-quote/"><strong>AGRI</strong></a>) shares are slipping over 10% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318425454&amp;type=PDF&amp;symbol=AGRI&amp;cdn=5153a3d8a3670dcb6c5185b3625a84cd&amp;companyName=AgriFORCE++Growing+Systems+Ltd.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-28">a delisting notice</a>.</li>



<li><strong>Assure </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/"><strong>IONM</strong></a>) stock closes out our pre-market stock movers down more than 10%.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-1st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Shares of Ardent Health slipped in their trading debut on Thursday after the hospital operator reduced its initial public offering from its proposed size and priced below the marketed range.

Ardent Health Slips After Downsized IPO

Lakeside Holding enters logistics agreement with e-commerce platform

Lakeside Holding launches new fulfillment service across U.S. for Chinese logistics and delivery company

Lakeside Holding acquires Hupan Pharmaceutical, entering the medical logistics sector

Lakeside Holding (LSH) is pleased to announce that through its wholly-owned subsidiary, Sichuan Hupan Jincheng Enterprise Management Co., has enter...

Lakeside Holding to acquire Hupan Pharmaceutical for $600,000

Lakeside Holding (LSH) subsidiary Hupan Pharmaceutical has signed a Sales Agreement with Sinopharm Holding Hubei New Special Medicine, a subsidiary...

Lakeside Holding signs $1.5M sales agreement with Sinopharm Group subsidiary

Lakeside enters into $1.5M sales deal with Sinopharm Hubei

AAGR

ACTU

AGRI

ALMS

ARDT

ARTV

BRFH

CHWY

CSSE

CSSEN

CSSEP

FVNNU

GDHG

HOLI

ICON

IONM

IXHL

LGHL

LICY

LPTV

MESO

MJID

NUKK

OSTX

QMMM

TWFG

WBTN

WLGS

Press Releases

LAKESIDE ENTERS INTO LOGISTICS AGREEMENT WITH LEADING E-COMMERCE PLATFORM

Lakeside Holding Partners With Leading Global Social Media and E-Commerce Platform to Streamline Cross-Border Fulfillment

LAKESIDE HOLDING LAUNCHES NEW PICK & PACK FULFILLMENT SERVICE ACROSS KEY U.S. HUBS FOR LONGSTANDING CHINA LOGISTICS PARTNER

LAKESIDE HOLDING EXPANDS DALLAS-FORT WORTH OPERATIONS WITH NEW OFFICE AND WAREHOUSE LEASE

Earnings

Lakeside Holding Reports Impressive 42% Revenue Growth for Fiscal Year 2024

Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.

LAKESIDE HOLDING PROVIDES FIRST QUARTER OF FISCAL YEAR 2025 RESULTS

Contracts

Lakeside Strengthens Market Position in China's Pharmaceutical Logistics with Key Sinopharm(Hubei) Contracts

Lakeside Holding to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary

Capital Clean Energy Carriers Corp. - Common Share

Capital Clean Energy

Costamare Inc. Common Stock $0.0001 par value

Costamare

Castor Maritime

Danaos

Diana Shipping

EuroDry

Euroseas

Globus Maritime

Genco Shipping & Trading Limited Ordinary Shares New (Marshall Islands)

Genco Shipping & Trading

Golden Ocean Group Limited - Common Stock

Golden Ocean Group

Global Ship Lease Inc New Class A Common Shares

Global Ship Lease

Himalaya Shipping

Caravelle International Group - Ordinary Shares

Caravelle Intl Gr

Kirby

Matson

Navios Maritime Partners LP Common Units Representing Limited Partner Interests

Navios Maritime Partners

Pangaea Logistics Solutions Ltd. - Common Stock

Pangaea Logistics Solns

Performance Shipping Inc. - Common Shares

Performance Shipping

Pyxis Tankers

Safe Bulkers, Inc Common Stock ($0.001 par value)

Safe Bulkers

Star Bulk Carriers

Seanergy Maritime Holdings Corp. - Common Stock

Seanergy Maritime Hldgs

Toro

United Maritime Corporation - Common Stock

United Maritime

ZIM Integrated Shipping Services Ltd. Ordinary Shares

Comments

Lakeside Holding

Noticias

Últimas noticias sobre Lakeside Holding (NASDAQ:LSH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL